Evidence map›Paper›PMID 37000264›Full record

Trial reportJournal of cancer research and clinical oncology2023

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).

Radoslav Chekerov, Tjadina Arndt, Klaus Pietzner, Ulrich Canzler, Pauline Wimberger, Hans-Georg Strauß, Sven Mahner, Linn Woelber, Nikolaus de Gregorio, Gertraud Stocker and 9 more

Open access · hybridAbstract readMulticenter StudyClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 1 country.

Radoslav Chekerov *Department of Gynaecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany. radoslav.chekerov@charite.de.
Tjadina Arndt *Department of Gynaecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Klaus PietznerDepartment of Gynaecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Ulrich CanzlerDepartment of Gynaecology and Obstetrics TU Dresden and National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.
Pauline WimbergerDepartment of Gynaecology and Obstetrics TU Dresden and National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.
Hans-Georg StraußDepartment of Gynaecology Universitätsklinik und Poliklinik, Martin-Luther University, Halle-Wittenberg, Germany.
Sven MahnerDepartment of Obstetrics and Gynaecology, University Hospital, Ludwig-Maximilian-University, Munich, Germany.
Linn WoelberDepartment of Gynaecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Nikolaus de GregorioDepartment of Obstetrics and Gynaecology, SLK Klinikum Heilbronn, Heilbronn, Germany.
Gertraud StockerMedical Department, University Cancer Center Leipzig (UCCL), University Medical Center, Leipzig, Germany.
Ekkehard von AbelDepartment of Obstetrics and Gynaecology, Stauferklinikum Schwäbisch Gmünd, Schwäbisch Gmünd, Germany.
Tanja NeunhoefferDepartment of Gynaecology, Helios Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany.
Antje Kristina BelauDepartment of Gynaecology, University of Greifswald, Greifswald, Germany.
Alexander MusteaDepartment of Gynaecology and Gynaecological Oncology, University of Bonn, Bonn, Germany.
Isil YalinkayaDepartment of Gynaecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Elena Ioana BraicuDepartment of Gynaecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Rolf RichterDepartment of Gynaecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Jalid SehouliDepartment of Gynaecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
NOGGO ovarian cancer study group
Charité - Universitätsmedizin Berlin · DEHumboldt-Universität zu Berlin · DETechnische Universität Dresden · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEHelios Dr. Horst Schmidt Kliniken Wiesbaden · DELudwig-Maximilians-Universität München · DEMartin Luther University Halle-Wittenberg · DESLK-Kliniken Heilbronn · DEUniversität Greifswald · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Bonn · DEUniversity of Design Schwäbisch Gmünd · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePazopanib has promising antiangiogenetic activity in solid cancers. The investigator-initiated phase I/II trial evaluated the combination of Topotecan with Pazopanib in platinum-resistant or intermediate-sensitive recurrent ovarian cancer (ROC).

methodsPatients (≥ 18 years) with first or second recurrence were enrolled in this multicentre open-label trial. Phase I analysed Topotecan 4 mg/m

resultsBetween June 2012 and February 2017, 11 patients were enrolled in the phase I, and 50 patients in the phase II study. The MTD of Pazopanib was determined by 400 mg/daily. Haematological and liver toxicities determined the dose limiting toxicities (DLT) and the most common grade 3-4 adverse events: leucopenia (25%), neutropenia (22%), thrombocytopenia (19%), accumulation of cholestatic (20%) and hepatocellular damage (15%), which often caused dose modifications, but no new life-threatening events. Overall response was 16% and clinical benefit rate 68%. Median progression-free survival (PFS) was 3.5 months (95% CI 2.0-5.0). Due to early progression only 20% of the patients were able to start with maintenance treatment.

conclusionThe combination of pazopanib and weekly topotecan is feasible, resulting in a manageable haematological and liver toxicity, but despite its encouraging response rate, was not associated with a significant survival benefit.

Indexed as

LeukopeniaOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialFemaleHumansIndazolesNeoplasm Recurrence, LocalPlatinumPyrimidinesSulfonamidesTopotecanIndazolespazopanibPlatinumPyrimidinesSulfonamidesTopotecanPazopanibPlatinum-resistant ovarian cancerTopotecan

Identifiers

PMID37000264
PMCPMC10374680
OpenAlexW4362459736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.